Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
Determining the effect of ivermectin on PCR test, clinical improvement, and duration of hospitalization in patients admitted with COVID-19
Determining the effect of ivermectin on RT-PCR test, clinical improvement, mortality and duration of hospitalization in patients admitted with COVID-19
Determining the effect of ivermectin on RT-PCR test, clinical improvement, mortality and duration of hospitalization in patients admitted with COVID-19
تعیین اثر Ivermectin بر تست PCR، بهبود بالینی و مدت بستری بیماران بستری مبتلا به COVID-19
تعیین اثر Ivermectin بر تست RT-PCR، بهبود بالینی، مرگ و میر و مدت بستری بیماران بستری مبتلا به COVID-19
تعیین اثر Ivermectin بر تست RT-PCR، بهبود بالینی، مرگ و میر و مدت بستری بیماران بستری مبتلا به COVID-19
Clinical trial with control group, parallel groups, double-blind, randomized, phase 3 on 500 patients. Patients will be divided into two groups by a simple randomization method with a table of random numbers. The control group will receive standard and placebo treatment and the intervention group will receive Ivermectin for three days in addition to the standard treatment.
Clinical trial with control group, parallel groups, double-blind, randomized, phase 3 on 1000 patients. Patients will be divided into two groups by a simple randomization method with a table of random numbers. The control group will receive standard and placebo treatment and the intervention group will receive Ivermectin for three days in addition to the standard treatment.
Clinical trial with control group, parallel groups, double-blind, randomized, phase 3 on 5001000 patients. Patients will be divided into two groups by a simple randomization method with a table of random numbers. The control group will receive standard and placebo treatment and the intervention group will receive Ivermectin for three days in addition to the standard treatment.
کارآزمایی بالینی دارای گروه کنترل، با گروه های موازی، دو سویه کور، تصادفی شده، فاز 3 بر روی 500 بیمار. بیماران با روش تصادفی سازی ساده با جدول اعداد تصادفی به دو گروه تقسیم می شوند. گروه کنترل درمان استاندارد و پلاسبو را دریافت کرده و گروه مداخله علاوه بر درمان استاندارد داروی Ivermectin به مدت سه روز دریافت خواهد کرد.
کارآزمایی بالینی دارای گروه کنترل، با گروه های موازی، دو سویه کور، تصادفی شده، فاز 3 بر روی 1000 بیمار. بیماران با روش تصادفی سازی ساده با جدول اعداد تصادفی به دو گروه تقسیم می شوند. گروه کنترل درمان استاندارد و پلاسبو را دریافت کرده و گروه مداخله علاوه بر درمان استاندارد داروی Ivermectin به مدت سه روز دریافت خواهد کرد.
کارآزمایی بالینی دارای گروه کنترل، با گروه های موازی، دو سویه کور، تصادفی شده، فاز 3 بر روی 5001000 بیمار. بیماران با روش تصادفی سازی ساده با جدول اعداد تصادفی به دو گروه تقسیم می شوند. گروه کنترل درمان استاندارد و پلاسبو را دریافت کرده و گروه مداخله علاوه بر درمان استاندارد داروی Ivermectin به مدت سه روز دریافت خواهد کرد.
COVID-19 positive rapid test or RT-PCR patients admitted to Buali and Imam hospitals of Sari and Razi hospital of Qaemshahr will be divided into two groups of intervention and control. The present study will be double-blind so that patients and physicians will be unaware of how the intervention and control groups assigned.
COVID-19 positive rapid test or RT-PCR patients admitted to Buali and Imam hospitals of Sari, Razi hospital of Qaemshahr, Imam Hossein hospital of Neka and Imam hospital of Fereidoonkenar will be divided into two groups of intervention and control. The present study will be double-blind so that patients and physicians will be unaware of how the intervention and control groups assigned.
COVID-19 positive rapid test or RT-PCR patients admitted to Buali and Imam hospitals of Sari and, Razi hospital of Qaemshahr, Imam Hossein hospital of Neka and Imam hospital of Fereidoonkenar will be divided into two groups of intervention and control. The present study will be double-blind so that patients and physicians will be unaware of how the intervention and control groups assigned.
بیماران رپید تست مثبت یا RT-PCR مثبت بستری در بیمارستانهای بوعلی و امام ساری و رازی قائم شهر به دو گروه مداخله و کنترل تقسیم می شوند. مطالعه حاضر دوسو کور است به طوری که بیماران و پزشک نسبت به نحوه تخصیص گروه مداخله و کنترل بی اطلاع خواهند بود.
بیماران رپید تست مثبت یا RT-PCR مثبت بستری در بیمارستانهای بوعلی و امام ساری، رازی قائم شهر، امام حسین نکا و امام فریدونکنار به دو گروه مداخله و کنترل تقسیم می شوند. مطالعه حاضر دوسو کور است به طوری که بیماران و پزشک نسبت به نحوه تخصیص گروه مداخله و کنترل بی اطلاع خواهند بود.
بیماران رپید تست مثبت یا RT-PCR مثبت بستری در بیمارستانهای بوعلی و امام ساری و، رازی قائم شهر، امام حسین نکا و امام فریدونکنار به دو گروه مداخله و کنترل تقسیم می شوند. مطالعه حاضر دوسو کور است به طوری که بیماران و پزشک نسبت به نحوه تخصیص گروه مداخله و کنترل بی اطلاع خواهند بود.
Intervention group: Iranian standard treatment protocol for COVID-19 in addition to Ivermectin for 3 days.
Control group: In the control group, placebo tablets made by the Department of Pharmacology of Mazandaran University of Medical Sciences with the same shape, color and weight based dose of ivermectin will be used for three days.
Intervention group: Iranian standard treatment protocol for COVID-19 in addition to 6mg Ivermectin tablet made by Alborz Daru Company of Iran for 3 days.
Control group: In the control group, placebo tablets made by Alborz Daru Company of Iran with the same shape, color and weight based dose of ivermectin will be used for three days.
Intervention group: Iranian standard treatment protocol for COVID-19 in addition to 6mg Ivermectin tablet made by Alborz Daru Company of Iran for 3 days. Control group: In the control group, placebo tablets made by the DepartmentAlborz Daru Company of Pharmacology of Mazandaran University of Medical SciencesIran with the same shape, color and weight based dose of ivermectin will be used for three days.
گروه مداخله: درکنار پروتکل استاندارد درمان COVID-19 ایران، از قرص خوراکی Ivermectin به مدت 3 روز استفاده خواهند کرد.
گروه کنترل: در گروه کنترل از قرص پلاسبو ساخت گروه فارماکولوژی دانشگاه علوم پزشکی مازندران با همان شکل، رنگ و دوز دارو به مدت سه روز طبق دوز ایورمکتین استفاده خواهد شد.
گروه مداخله: درکنار پروتکل استاندارد درمان COVID-19 ایران، از قرص خوراکی Ivermectin شش میلی گرمی ساخت شرکت البرز دارو ایران به مدت 3 روز استفاده خواهند کرد.
گروه کنترل: در گروه کنترل از قرص پلاسبو ساخت شرکت البرز دارو ایران با همان شکل، رنگ و دوز دارو به مدت سه روز طبق دوز ایورمکتین استفاده خواهد شد.
گروه مداخله: درکنار پروتکل استاندارد درمان COVID-19 ایران، از قرص خوراکی Ivermectin شش میلی گرمی ساخت شرکت البرز دارو ایران به مدت 3 روز استفاده خواهند کرد. گروه کنترل: در گروه کنترل از قرص پلاسبو ساخت گروه فارماکولوژی دانشگاه علوم پزشکی مازندرانشرکت البرز دارو ایران با همان شکل، رنگ و دوز دارو به مدت سه روز طبق دوز ایورمکتین استفاده خواهد شد.
Negative PCR; cough; tachypnea; O2 saturation.
Clinical improvement, Duration of hospital stay, Rate of Mortality
Negative PCR; cough; tachypnea; O2 saturation.Clinical improvement, Duration of hospital stay, Rate of Mortality
منفی شدن PCR؛ سرفه؛ تاکی پنه؛ O2 saturation
بهبود بالینی، مدت بستری، میزان مرگ و میر
منفی شدن PCR؛ سرفه؛ تاکی پنه؛ O2 saturationبهبود بالینی، مدت بستری، میزان مرگ و میر
General information
500
1000
5001000
2021-06-21, 1400/03/31
2021-08-22, 1400/05/31
2021-0608-2122 00:00:00
empty
Increase in sample size and pharmaceutic company
Increase in sample size and pharmaceutic company
empty
افزایش حجم نمونه و تغییر شرکت دارویی
افزایش حجم نمونه و تغییر شرکت دارویی
Underlying liver and kidney disease
Patients with acquired immunodeficiency
Consumption of warfarin and ACEI family drugs (captopril, enalapril, etc.)
Pregnancy and lactation
Underlying liver and kidney disease
Patients with acquired immunodeficiency
Pregnancy and lactation
Underlying liver and kidney disease Patients with acquired immunodeficiency Consumption of warfarin and ACEI family drugs (captopril, enalapril, etc.) Pregnancy and lactation
بیماری کبدی و کلیوی زمینه ای
بیماران با نقص ایمنی اکتسابی
مصرف وارفارین و داروهای خانواده ACEI (کاپتوپریل، انالاپریل و ...)
بارداری و شیردهی
بیماری کبدی و کلیوی زمینه ای
بیماران با نقص ایمنی اکتسابی
بارداری و شیردهی
بیماری کبدی و کلیوی زمینه ای بیماران با نقص ایمنی اکتسابی مصرف وارفارین و داروهای خانواده ACEI (کاپتوپریل، انالاپریل و ...) بارداری و شیردهی
First, using the Random number generation plugin in excel software, a table of random numbers from 1 to 500 is prepared in a non-sequential and scattered manner, and the numbers are assigned to two intervention and control groups of 250 cases. The randomization process is performed by the methodology consultant and clinical researchers are not aware of the randomization process and will only be provided with random codes from 1 to 500.
First, using the Random number generation plugin in excel software, a table of random numbers from 1 to 1000 is prepared in a non-sequential and scattered manner, and the numbers are assigned to two intervention and control groups of 500 cases. The randomization process is performed by the methodology consultant and clinical researchers are not aware of the randomization process and will only be provided with random codes from 1 to 1000.
First, using the Random number generation plugin in excel software, a table of random numbers from 1 to 5001000 is prepared in a non-sequential and scattered manner, and the numbers are assigned to two intervention and control groups of 250500 cases. The randomization process is performed by the methodology consultant and clinical researchers are not aware of the randomization process and will only be provided with random codes from 1 to 5001000.
ابتدا با استفاده از افزونه Random number generation در نرم افزار excel جدول اعداد تصادفی از 1 تا 500 به صورت نامتوالی و پراکنده تهیه شده و توسط نرم افزار تخصیص اعداد به دو گروه 250 نفره مداخله و کنترل صورت می گیرد. فرایند تصادفی سازی توسط مشاور متدولوژی مطالعه است و محققین بالینی از فرایند تصادفی سازی اطلاع ندارند و فقط کدهای تصادفی شده از 1 تا 500 در اختیارشان قرار خواهد گرفت.
ابتدا با استفاده از افزونه Random number generation در نرم افزار excel جدول اعداد تصادفی از 1 تا 1000 به صورت نامتوالی و پراکنده تهیه شده و توسط نرم افزار تخصیص اعداد به دو گروه 500 نفره مداخله و کنترل صورت می گیرد. فرایند تصادفی سازی توسط مشاور متدولوژی مطالعه است و محققین بالینی از فرایند تصادفی سازی اطلاع ندارند و فقط کدهای تصادفی شده از 1 تا 1000 در اختیارشان قرار خواهد گرفت.
ابتدا با استفاده از افزونه Random number generation در نرم افزار excel جدول اعداد تصادفی از 1 تا 5001000 به صورت نامتوالی و پراکنده تهیه شده و توسط نرم افزار تخصیص اعداد به دو گروه 250500 نفره مداخله و کنترل صورت می گیرد. فرایند تصادفی سازی توسط مشاور متدولوژی مطالعه است و محققین بالینی از فرایند تصادفی سازی اطلاع ندارند و فقط کدهای تصادفی شده از 1 تا 5001000 در اختیارشان قرار خواهد گرفت.
Primary outcomes
#1
Negative PCR result
Negative RT-PCR result
Negative RT-PCR result
منفی شدن PCR
منفی شدن RT-PCR
منفی شدن RT-PCR
Intervention groups
#1
Intervention group: The intervention group will use Iranian standard treatment protocol for COVID-19 in addition to Ivermectin 3 mg oral tablet at a dose of 0.4 mg/kg manufactured by Europhartech France for 3 days as follows: weight 15-24, 6 mg; Weight 35-25, 12 mg; Weight 50-36, 18 mg; Weight 80-5, 24 mg and weight over 80, 0.4 mg/kg
Intervention group: The intervention group will use Iranian standard treatment protocol for COVID-19 in addition to Ivermectin 3 mg oral tablet at a dose of 0.4 mg/kg manufactured by Alborz Daru of Iran for 3 days as follows: weight 15-24, 6 mg; Weight 35-25, 12 mg; Weight 50-36, 18 mg; Weight 80-5, 24 mg and weight over 80, 0.4 mg/kg
Intervention group: The intervention group will use Iranian standard treatment protocol for COVID-19 in addition to Ivermectin 3 mg oral tablet at a dose of 0.4 mg/kg manufactured by Europhartech FranceAlborz Daru of Iran for 3 days as follows: weight 15-24, 6 mg; Weight 35-25, 12 mg; Weight 50-36, 18 mg; Weight 80-5, 24 mg and weight over 80, 0.4 mg/kg
گروه مداخله: گروه مداخله درکنار پروتکل استاندارد درمان COVID-19 ایران، از قرص خوراکی Ivermectin سه میلی گرمی با دوز 0.4 میلی گرم به ازای وزن بدن ساخت یوروفارتک فرانسه به مدت 3 روز به صورت زیر استفاده خواهند کرد: وزن 24-15، 6 میلی گرم؛ وزن 35-25 دوز 12میلی گرم؛ وزن 50-36 دوز 18 میلی گرم؛ وزن 80-51 دوز 24میلی گرم و وزن بالای 80 دوز 0.4 میلی گرم به ازای وزن بدن
گروه مداخله: گروه مداخله درکنار پروتکل استاندارد درمان COVID-19 ایران، از قرص خوراکی Ivermectin شش میلی گرمی با دوز 0.4 میلی گرم به ازای وزن بدن ساخت شرکت البرز دارو ایران به مدت 3 روز به صورت زیر استفاده خواهند کرد: وزن 24-15، 6 میلی گرم؛ وزن 35-25 دوز 12میلی گرم؛ وزن 50-36 دوز 18 میلی گرم؛ وزن 80-51 دوز 24میلی گرم و وزن بالای 80 دوز 0.4 میلی گرم به ازای وزن بدن
گروه مداخله: گروه مداخله درکنار پروتکل استاندارد درمان COVID-19 ایران، از قرص خوراکی Ivermectin سهشش میلی گرمی با دوز 0.4 میلی گرم به ازای وزن بدن ساخت یوروفارتک فرانسهشرکت البرز دارو ایران به مدت 3 روز به صورت زیر استفاده خواهند کرد: وزن 24-15، 6 میلی گرم؛ وزن 35-25 دوز 12میلی گرم؛ وزن 50-36 دوز 18 میلی گرم؛ وزن 80-51 دوز 24میلی گرم و وزن بالای 80 دوز 0.4 میلی گرم به ازای وزن بدن
#2
Control group: In the control group, placebo tablets made by the Department of Pharmacology of Mazandaran University of Medical Sciences with the same shape, color and weight based dose of ivermectin will be used for three days.
Control group: In the control group, placebo tablets made by Alborz Daru of Iran with the same shape, color and weight based dose of ivermectin will be used for three days.
Control group: In the control group, placebo tablets made by the DepartmentAlborz Daru of Pharmacology of Mazandaran University of Medical SciencesIran with the same shape, color and weight based dose of ivermectin will be used for three days.
گروه کنترل: در گروه کنترل از قرص پلاسبو ساخت گروه فارماکولوژی دانشگاه علوم پزشکی مازندران با همان شکل، رنگ و دوز دارو به مدت سه روز طبق دوز ایورمکتین استفاده خواهد شد.
گروه کنترل: در گروه کنترل از قرص پلاسبو ساخت شرکت البرز دارو ایران با همان شکل، رنگ و دوز دارو به مدت سه روز طبق دوز ایورمکتین استفاده خواهد شد.
گروه کنترل: در گروه کنترل از قرص پلاسبو ساخت گروه فارماکولوژی دانشگاه علوم پزشکی مازندرانشرکت البرز دارو ایران با همان شکل، رنگ و دوز دارو به مدت سه روز طبق دوز ایورمکتین استفاده خواهد شد.
Recruitment centers
#1
Name of recruitment center - English: Imam and Buali hospitals of Sari and Razi hopspital of Qaemshahr
Name of recruitment center - Persian: بیمارستان امام و بوعلی ساری و رازی قائمشهر
Full name of responsible person - English: Dr Mohammad Sadegh Rezai
Full name of responsible person - Persian: دکتر محمدصادق رضایی
Street address - English: Bouali Hospital, Pasdaran boulevard, Sari
Street address - Persian: ساری، بلوار پاسداران، بیمارستان بوعلی
City - English: Sari
City - Persian: ساری
Province: Mazandaran
Country: Iran (Islamic Republic of)
Postal code: 4815838477
Phone: +98 11 3334 2334
Fax:
Email: drmsrezaii@yahoo.com
Web page address:
Name of recruitment center - English: Imam and Buali hospitals of Sari, Razi hopspital of Qaemshahr, Imam Hossein hospital of Neka and Ima
Name of recruitment center - Persian: بیمارستان امام و بوعلی ساری، رازی قائمشهر، امام حسین نکا و امام فریدونکنار
Full name of responsible person - English: Dr Mohammad Sadegh Rezai
Full name of responsible person - Persian: دکتر محمدصادق رضایی
Street address - English: Bouali Hospital, Pasdaran boulevard, Sari
Street address - Persian: ساری، بلوار پاسداران، بیمارستان بوعلی
City - English: Sari
City - Persian: ساری
Province: Mazandaran
Country: Iran (Islamic Republic of)
Postal code: 4815838477
Phone: +98 11 3334 2334
Fax:
Email: drmsrezaii@yahoo.com
Web page address:
Name of recruitment center - English: Imam and Buali hospitals of Sari and, Razi hopspital of Qaemshahr, Imam Hossein hospital of Neka and Ima Name of recruitment center - Persian: بیمارستان امام و بوعلی ساری و، رازی قائمشهر، امام حسین نکا و امام فریدونکنار Full name of responsible person - English: Dr Mohammad Sadegh Rezai Full name of responsible person - Persian: دکتر محمدصادق رضایی Street address - English: Bouali Hospital, Pasdaran boulevard, Sari Street address - Persian: ساری، بلوار پاسداران، بیمارستان بوعلی City - English: Sari City - Persian: ساری Province: Mazandaran Country: Iran (Islamic Republic of) Postal code: 4815838477 Phone: +98 11 3334 2334 Fax: Email: drmsrezaii@yahoo.com Web page address:
Protocol summary
Study aim
Determining the effect of ivermectin on RT-PCR test, clinical improvement, mortality and duration of hospitalization in patients admitted with COVID-19
Design
Clinical trial with control group, parallel groups, double-blind, randomized, phase 3 on 1000 patients. Patients will be divided into two groups by a simple randomization method with a table of random numbers. The control group will receive standard and placebo treatment and the intervention group will receive Ivermectin for three days in addition to the standard treatment.
Settings and conduct
COVID-19 positive rapid test or RT-PCR patients admitted to Buali and Imam hospitals of Sari, Razi hospital of Qaemshahr, Imam Hossein hospital of Neka and Imam hospital of Fereidoonkenar will be divided into two groups of intervention and control. The present study will be double-blind so that patients and physicians will be unaware of how the intervention and control groups assigned.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Patients with COVID-19 positive rapid test or RT-PCR; aged >5 years; weight more than 15 kg and without liver and lung disease and acquired immunodeficiency and pregnancy lactation and without treatment with antiviral drugs before and during the study are included.
Intervention groups
Intervention group: Iranian standard treatment protocol for COVID-19 in addition to 6mg Ivermectin tablet made by Alborz Daru Company of Iran for 3 days.
Control group: In the control group, placebo tablets made by Alborz Daru Company of Iran with the same shape, color and weight based dose of ivermectin will be used for three days.
Main outcome variables
Clinical improvement, Duration of hospital stay, Rate of Mortality
General information
Reason for update
Increase in sample size and pharmaceutic company
Acronym
IRCT registration information
IRCT registration number:IRCT20111224008507N5
Registration date:2021-02-22, 1399/12/04
Registration timing:registered_while_recruiting
Last update:2021-03-04, 1399/12/14
Update count:1
Registration date
2021-02-22, 1399/12/04
Registrant information
Name
Mohammadsadegh Rezai
Name of organization / entity
Mazandaran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 15 1325 7230
Email address
rezai@mazums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-02-19, 1399/12/01
Expected recruitment end date
2021-08-22, 1400/05/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Double-blind placebo-controlled clinical trial of evaluating the effectiveness of Ivermectin in treatment of patients admitted with COVID-19 in 2021
Public title
Evaluation of the effect of Ivermectin in treatment of patients admitted with COVID-19
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients with positive coronavirus rapid test or RT-PCR
Age>5 years
Weight >15 kg
No treatment with antiviral drugs before and during the study
Informed consent for participation
Exclusion criteria:
Underlying liver and kidney disease
Patients with acquired immunodeficiency
Pregnancy and lactation
Age
From 5 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Investigator
Sample size
Target sample size:
1000
Randomization (investigator's opinion)
Randomized
Randomization description
First, using the Random number generation plugin in excel software, a table of random numbers from 1 to 1000 is prepared in a non-sequential and scattered manner, and the numbers are assigned to two intervention and control groups of 500 cases. The randomization process is performed by the methodology consultant and clinical researchers are not aware of the randomization process and will only be provided with random codes from 1 to 1000.
Blinding (investigator's opinion)
Double blinded
Blinding description
After selecting the samples, none of the participants will be aware of randomization and allocation to groups. Physicians will be given a table of pre-coded numbered numbers and patients will be entered into the study in order of table numbers. Therefore, the present study will be double-blind. Ivermectin and placebo tablets will be in the same shape, color and size and will be delivered to the patient/parents in a package.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Mazandaran University of Medical Sciences
Street address
Vice chancellor for Research, Moallem square, Sari
City
Sari
Province
Mazandaran
Postal code
4712855689
Approval date
2021-01-27, 1399/11/08
Ethics committee reference number
IR.MAZUMS.REC.1399.915
Health conditions studied
1
Description of health condition studied
COVID-19 infection
ICD-10 code
U07.1
ICD-10 code description
COVID-19, virus identified
Primary outcomes
1
Description
Reduction in persistent cough
Timepoint
Daily until improvement
Method of measurement
Question from the patient
2
Description
Negative RT-PCR result
Timepoint
6 days after the intervention
Method of measurement
RT-PCR
3
Description
The main complaints recovery time
Timepoint
Daily until symptoms resolve
Method of measurement
Checklist containing patient complaints
4
Description
Mortality
Timepoint
Daily
Method of measurement
Record in checklist
5
Description
Drug side effect (Wheezing, itching, skin rash, edema, and hypotension)
Timepoint
Daily
Method of measurement
Question from the patient
6
Description
Reduction in tachypnea
Timepoint
Daily
Method of measurement
Medical record
7
Description
Oxigen saturation >94%
Timepoint
Daily
Method of measurement
Medical record
Secondary outcomes
empty
Intervention groups
1
Description
Intervention group: The intervention group will use Iranian standard treatment protocol for COVID-19 in addition to Ivermectin 3 mg oral tablet at a dose of 0.4 mg/kg manufactured by Alborz Daru of Iran for 3 days as follows: weight 15-24, 6 mg; Weight 35-25, 12 mg; Weight 50-36, 18 mg; Weight 80-5, 24 mg and weight over 80, 0.4 mg/kg
Category
Treatment - Drugs
2
Description
Control group: In the control group, placebo tablets made by Alborz Daru of Iran with the same shape, color and weight based dose of ivermectin will be used for three days.
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Imam and Buali hospitals of Sari, Razi hopspital of Qaemshahr, Imam Hossein hospital of Neka and Ima
Full name of responsible person
Dr Mohammad Sadegh Rezai
Street address
Bouali Hospital, Pasdaran boulevard, Sari
City
Sari
Province
Mazandaran
Postal code
4815838477
Phone
+98 11 3334 2334
Email
drmsrezaii@yahoo.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr. Majid Saeidi
Street address
Vice chancellor for Research, Moallem square, Sari
City
Sari
Province
Mazandaran
Postal code
4712855689
Phone
+98 11 3334 2334
Email
msaidi@mazums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mazandaran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Mohammad Sadegh Rezai
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Boali Hospital, Pasdaran Blv., Sari
City
Sari
Province
Mazandaran
Postal code
4815838477
Phone
+98 11 3334 2334
Fax
+98 11 3334 2334
Email
drmsrezaii@yahoo.com
Web page address
Person responsible for scientific inquiries
Contact
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Mohammad Sadegh Rezai
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Bouali Hospital, Pasdaran Boulevard, Sari
City
Sari
Province
Mazandaran
Postal code
4815838477
Phone
+98 11 3334 2334
Email
drmsrezaii@yahoo.com
Person responsible for updating data
Contact
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Fatemeh Hosseinzadeh
Position
Research Expert
Latest degree
Master
Other areas of specialty/work
Midwifery
Street address
Bouali Hospital, Pasdaran Boulevard, Sari
City
Sari
Province
Mazandaran
Postal code
4815838477
Phone
+98 11 3334 2334
Email
fatima.hzade@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
Part of the data is accessible
When the data will become available and for how long
Starting in January 2022
To whom data/document is available
Physicians
Under which criteria data/document could be used
Systematic review articles
From where data/document is obtainable
Contact Dr. Mohammad Sadegh Rezai. E-mail: drmsrezaii@yahoo.com
What processes are involved for a request to access data/document
After contact, information is sent within a few days